

1. A lubricating polypeptide comprising amino acids 67-106 and 200-1140 of SEQ ID NO:1 and at least one O-linked oligosaccharide, wherein said polypeptide lacks amino acids 26-66 of SEQ ID NO:1.
- 5 2. A lubricating polypeptide comprising amino acids 67-106 and 200-1140 of SEQ ID NO:1 and at least one O-linked oligosaccharide, wherein said polypeptide lacks amino acids 107-156 of SEQ ID NO:1.
3. A lubricating polypeptide comprising amino acids 67-106 and 200-1140 of SEQ ID NO:1 and at least one O-linked oligosaccharide, wherein said polypeptide lacks amino acids 157-199 of SEQ ID NO:1.
- 10 4. The polypeptide of claim 1, wherein said polypeptide further lacks amino acids 107-156 of SEQ ID NO:1.
5. The polypeptide of claim 1, wherein said polypeptide further lacks amino acids 107-199 of SEQ ID NO:1.
- 15 6. The polypeptide of claim 1, wherein said polypeptide comprises amino acids 1-25, 67-106, and 200-1404 of SEQ ID NO:1.
7. The polypeptide of claim 3, wherein said polypeptide comprises amino acids 1-156 and 200-1404 of SEQ ID NO:1.
8. The polypeptide of claim 3, wherein said polypeptide comprises amino acids 1-106 and 200-1404.
- 20 9. A polynucleotide comprising nucleotides 232-351 and 631-3453 of SEQ ID NO:2 and lacking nucleotides 109-231 of SEQ ID NO:2.
10. A polynucleotide comprising nucleotides 232-351 and 631-3453 of SEQ ID NO:2 and lacking nucleotides 352-501 of SEQ ID NO:2.
- 25 11. A polynucleotide comprising nucleotides 232-351 and 631-3453 of SEQ ID NO:2 and lacking nucleotides 502-630 of SEQ ID NO:2.
12. A polynucleotide comprising nucleotides 232-351 and 631-3453 of SEQ ID NO:2 and lacking nucleotides 352-630 of SEQ ID NO:2.
13. A polynucleotide comprising nucleotides 232-351 and 631-3453 of SEQ ID NO:2 and lacking nucleotides 109-231 and 352-630 of SEQ ID NO:2.
- 30

14. A polynucleotide comprising nucleotides 34-501 linked in-frame to nucleotides 631-4245 of SEQ ID NO:2.
15. A polynucleotide comprising nucleotides 34-501 linked in-frame to nucleotides 631-4245 of SEQ ID NO:2.
16. A polynucleotide comprising a first sequence comprising nucleotides 34-501 of SEQ ID NO:2, a second sequence comprising nucleotides 232-351 of SEQ ID NO:2, and a third sequence comprising nucleotides 631-4245 of SEQ ID NO:2, wherein said first, second and third sequences are linked in-frame.
17. The polypeptide of claim 1, 2, or 3, wherein said O-linked oligosaccharide is a $\beta(1-3)$ Gal-GalNAc.
18. A method of reducing a symptom of Camptodactyl-arthropathy-pericarditis syndrome (CAP) in a mammal, comprising administering to said mammal a megakaryocyte stimulating factor polypeptide or an alternatively spliced variant thereof.
19. The method of claim 19, wherein said polypeptide comprises comprising amino acids 67-106 and 200-1140 of SEQ ID NO:1 and at least one O-linked oligosaccharide and wherein said polypeptide lacks amino acids 157-199 of SEQ ID NO:1.
20. A method of reducing a symptom of CAP in a mammal, comprising administering to said mammal a polynucleotide encoding MSF or an alternatively spliced variant thereof.
21. The method of claim 20, wherein said polynucleotide comprises nucleotides 232-351 and 631-3453 of SEQ ID NO:2 and lacks nucleotides 502-630 of SEQ ID NO:2.
22. A method of reducing a symptom of osteoarthritis in a mammal, comprising administering to said mammal a megakaryocyte stimulating factor polypeptide or an alternatively spliced variant thereof.
23. The method of claim 19, wherein said polypeptide comprises comprising amino acids 67-106 and 200-1140 of SEQ ID NO:1 and at least one O-linked oligosaccharide and wherein said polypeptide lacks amino acids 157-199 of SEQ ID NO:1.
24. A method of reducing a symptom of osteoarthritis in a mammal, comprising administering to said mammal a polynucleotide encoding MSF or an alternatively spliced variant thereof.
25. The method of claim 20, wherein said polynucleotide comprises nucleotides 232-351 and 631-3453 of SEQ ID NO:2 and lacks nucleotides 502-630 of SEQ ID NO:2.